Beijing Tongrentang Co Ltd (600085)
Shanghai Stock Exchange · China · prices in CNY · close of 19 Oct 2026
Key indicators
| Last close | CNY 25.33 |
|---|---|
| 52-week range | 21.40 – 35.87 |
| Return, 1 month / 3 months | +6.9% / +2.3% |
| Return, 1 year / 3 years | −25.8% / −55.7% |
| Trend | Below its 200-day average |
| RSI (14) | 68 |
| Volatility (1 year) | 21.0% |
| Worst drawdown (1 year) | -38.0% |
| Average daily value traded | 186.68M CNY |
| Dividend yield | – |
Market X-Ray price-based
Five-year price chart navy: price · brown: 200-day average
About the company
Beijing Tongrentang is a Chinese pharmaceutical company that makes and sells traditional Chinese medicines, herbal remedies and health products under its long-established brand. It produces patent medicines in pill, powder and ointment forms and runs a chain of pharmacies and clinics where its products are dispensed. Its customers are mainly consumers in China seeking traditional treatments and health supplements, and the company is based in Beijing.
The shares are listed on the Shanghai Stock Exchange in China under the code 600085, and the price on this page is in Chinese yuan (CNY). Our dividend records, which start in 2019, show payments in 5 different calendar years. The Market X-Ray on this page is price-based and compares it with other stocks on the same exchange; it does not measure how healthy the business is.
Summary
Beijing Tongrentang Co Ltd (600085) trades on the Shanghai Stock Exchange in China. It last closed at CNY 25.33 on 19 October 2026.
Its price-based Market X-Ray is 63 out of 100 (a fair price profile), ranking 574 of 2,278 stocks on this exchange. The score describes how the stock has traded: trend, momentum, risk, liquidity and dividends, each ranked against the other stocks on its own exchange. It does not measure how healthy or cheap the business is.
Over the last year the price fell 25.8% and over the last three months it rose 2.3%. Returns are price returns, dividends not included.
Fundamental measures (valuation, growth, financial health) are not shown: we do not yet hold financial statements for this market.
The five lenses in numbers each metric is ranked against the other stocks on Shanghai Stock Exchange
| Lens and metric | Value | Score | Reading |
|---|---|---|---|
| Trend | 61 · Fair | Mixed trend against its averages. | |
| Above 200-day average | -6.4% | ||
| From 52-week high | -28.3% | ||
| Momentum | 49 · Weak | Lagging most stocks on this exchange. | |
| 3-month return | 2.3% | ||
| 6-month return | -8.9% | ||
| 12-month return, skipping the last month | -30.6% | ||
| Stability (higher is calmer) | 81 · Strong | Calmer than most: low volatility and shallow drawdowns. | |
| Volatility, 1 year (lower is calmer) | 21.0% | ||
| Worst drawdown, 1 year (smaller is calmer) | -38.0% | ||
| Liquidity | 60 · Fair | Moderate trading activity. | |
| Average daily value traded | 186.68M CNY | ||
| Zero-volume days | 0.0% | ||
| Income | – | Pays no dividend. | |
| Dividend yield | – | ||
| Years with dividends | 2 |
Strengths
- Stability (higher is calmer): Calmer than most: low volatility and shallow drawdowns.
Weak spots
- Momentum: Lagging most stocks on this exchange.
Returns
| 1 week | +3.7% |
|---|---|
| 1 month | +6.9% |
| 3 months | +2.3% |
| 6 months | −8.9% |
| 1 year | −25.8% |
| 3 years | −55.7% |
| 5 years | – |
Signals
| 50-day / 200-day average | 24.20 / 27.06 |
|---|---|
| Golden / death cross (60 days) | None |
| New 52-week high | No |
| Bullish RSI divergence | No |
| Average daily range (ATR) | 0.50 |
Technical summary
Recent dividends
| Ex-dividend date | Amount per share |
|---|---|
| 24 Jul 2023 | CNY 0.3200 |
| 18 Aug 2022 | CNY 0.2900 |
| 12 Aug 2021 | CNY 0.2700 |
| 20 Jul 2020 | CNY 0.2600 |
| 9 Dec 2019 | CNY 0.5000 |
| 29 Jul 2019 | CNY 0.2600 |
How to read this report
Every number comes from end-of-day prices and dividends. The Market X-Ray describes how the stock has traded, ranked against the other stocks on Shanghai Stock Exchange; it does not measure how healthy or cheap the business is. The fundamental X-Ray (financial health, valuation, growth) needs financial statements, which we hold today for US stocks. See the methodology page. Educational only, not financial advice.